Orca-T improves AML survival in phase Ib trial subgroup

NCI’s myeloMATCH will use biomarkers to match patients with myeloid cancer to trials

NCI has launched a second-generation precision medicine clinical trial called Myeloid Malignancies Molecular Analysis for Therapy Choice, or myeloMATCH, a trial focused on acute myeloid leukemia and myelodysplastic syndromes.

October 25, 2024

Vol.50 No.40

By Claire Marie Porter

Drugs & Targets

NeoGenomics launches NGS assay for AML

AML Express, a next-generation sequencing assay designed to provide rapid, comprehensive genetic profiling for patients with acute myeloid leukemia, was announced by NeoGenomics Inc.

October 11, 2024

Vol.50 No.38

Drugs & Targets

FDA grants Fast Track designation for ICT01 + Azacitidine + Venetoclax in treatment of first-line AML unfit for induction chemo

FDA granted Fast Track designation to ICT01 in combination with azacitidine and venetoclax for the treatment of acute myeloid leukemia patients 75 years or older, or who have comorbidities that preclude use of standard intensive induction chemotherapy.

September 20, 2024

Vol.50 No.35

Clinical Roundup

Shorter durations of venetoclax yields similar response rates in AML

When combined with azacitidine, a 7-day course of venetoclax demonstrated similar remission rates and was more tolerable compared to the standard 28-day course for older or chemotherapy-ineligible patients with newly diagnosed acute myeloid leukemia. Results from the retrospective multi-center analysis were presented by Alexandre Bazinet, assistant professor of leukemia at MD Anderson, at the 2024 American Society of Clinical Oncology Annual Meeting.

June 07, 2024

Vol.50 No.23

Clinical Roundup

Older adults with aggressive blood cancer are responsive to treatment and show prolonged survival

Standard of care treatment for acute myeloid leukemia is safe and effective for adults over 80, according to a study published in Blood Neoplasia. For roughly a quarter of patients, this treatment can durably prolong survival.

May 17, 2024

Vol.50 No.20

Clinical Roundup

Lower MRD prior to HCT associated with better outcomes in FLT3-ITD AML

Patients in remission after being treated for a high-risk blood cancer are likely to have better outcomes if no trace of the cancer is detectable before the patients receive donor blood cells.

May 03, 2024

Vol.50 No.18

Orca-T improves AML survival in phase Ib trial subgroup

YOU MAY BE INTERESTED IN

NCI’s myeloMATCH will use biomarkers to match patients with myeloid cancer to trials

NeoGenomics launches NGS assay for AML

FDA grants Fast Track designation for ICT01 + Azacitidine + Venetoclax in treatment of first-line AML unfit for induction chemo

Shorter durations of venetoclax yields similar response rates in AML

Older adults with aggressive blood cancer are responsive to treatment and show prolonged survival

Lower MRD prior to HCT associated with better outcomes in FLT3-ITD AML

Renew today!

Subscriber content

Login